弥漫大B细胞淋巴瘤中期PET的预测价值:系统综述与Meta分析
该系统综述与Meta分析检索至2017年7月11日,纳入未依据中期PET结果调整治疗的前瞻性与回顾性研究,评估视觉评估中期18F-FDG PET对接受一线免疫化疗的弥漫大B细胞淋巴瘤患者无进展生存或事件生存的预测价值。18项研究共2255例的合并风险比为3.13(95%CI 2.52-3.89),95%预测区间1.68-5.83;19项研究共2366例的阴性预测值一般超过80%(64-95),但敏感度(33-87)、特异度(49-94)与阳性预测值(20-74)范围较宽。
要点
- 中期18F-FDG PET对DLBCL患者有预测价值,合并HR为3.13(95%CI 2.52-3.89)。
- 阴性预测值一般超过80%(64-95),但敏感度、特异度与阳性预测值范围较宽。
- 阳性预测值有待提高,之后才能在临床实践中实施成功的风险分层治疗。
核心结论
- 中期18F-FDG PET在DLBCL患者中具有预测价值。
- 亚组分析受信息缺乏与样本量小限制。
- 部分诊断试验特征不令人满意,尤其阳性预测值有待提高,之后才能在临床实践中实施成功的风险分层治疗。
研究设计与样本
- 系统综述与Meta分析,检索Pubmed、Embase与Cochrane Library至2017年7月11日。
- 纳入研究中期PET定性反应评估且不依据中期PET结果调整治疗的前瞻性与回顾性研究。
- 主要结局为2年无进展生存或事件生存。
- 提取并分析预后与诊断指标,分别采用合并风险比与分层汇总受试者工作特征曲线。
- 采用Meta回归研究协变量效应。
主要发现
- 18项研究共2255例的合并风险比为3.13(95%CI 2.52-3.89),95%预测区间为1.68-5.83。
- 19项研究共2366例中,对进展的阴性预测值一般超过80%(64-95)。
- 敏感度(33-87)、特异度(49-94)与阳性预测值(20-74)范围较宽。
局限性
- 亚组分析受信息缺乏与样本量小限制。
- 部分诊断试验特征不令人满意,尤其阳性预测值有待提高,之后才能在临床实践中实施成功的风险分层治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Diffuse large B-cell lymphoma (DLBCL) represents the most common subtype of non-Hodgkin lymphoma. Most relapses occur in the first 2 years after diagnosis. Early response assessment with 18F-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography (PET) may facilitate early change of treatment, thereby preventing ineffective treatment and unnecessary side effects. We aimed to assess the predictive value of visually-assessed interim 18F-FDG PET on progression-free survival (PFS) or event-free survival (EFS) in DLBCL patients treated with first-line immuno-chemotherapy regimens. METHODS: For this systematic review and meta-analysis Pubmed, Embase, and the Cochrane Library were searched until July 11, 2017. Prospective and retrospective studies investigating qualitative interim PET response assessment without treatment adaptation based on the interim PET result were eligible. The primary outcome was two-year PFS or EFS. Prognostic and diagnostic measures were extracted and analysed with pooled hazard ratios and Hierarchical Summary Receiver Operator Characteristic Curves, respectively. Meta-regression was used to study covariate effects. RESULTS: The pooled hazard ratio for 18 studies comprising 2,255 patients was 3.13 (95%CI 2.52-3.89) with a 95% prediction interval of 1.68-5.83. In 19 studies with 2,366 patients, the negative predictive value for progression generally exceeded 80% (64-95), but sensitivity (33-87), specificity (49-94), and positive predictive values (20-74) ranged widely. CONCLUSIONS: These findings showed that interim 18F-FDG PET has predictive value in DLBCL patients. However, (subgroup) analyses were limited by lack of information and small sample sizes. Some diagnostic test characteristics were not satisfactory, especially the positive predictive value should be improved, before a successful risk stratified treatment approach can be implemented in clinical practice.
引用
- Burggraaff CN, de Jong A, Hoekstra OS, et al. Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2018. PMID: 30141066. doi:10.1007/s00259-018-4103-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。